Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Comparative Analysis for Effectiveness of Azacitidine Versus Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes with Marrow Fibrosis: A Single Institution Experience

Ala Ebaid, MD, Shashank Y. Cingam, MBBS, Tawny Boyce, MS, MPH, Daniel Babu, MD, Qiuying Selina Liu, MD, Khine Win, Cecilia Y. Arana Yi, MD

Blood (2019) 134 (Supplement_1): 5099.

https://doi.org/10.1182/blood-2019-131881

Published: 2019

Journal Articles

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Qiuying Selina Liu, MD, Shashank Y. Cingam, MBBS, Khine Z Win, MD, Tawny Boyce, MS, MPH, Cecilia Y. Arana Yi, MD

Blood (2019) 134 (Supplement_1): 5379.

https://doi.org/10.1182/blood-2019-132142

Published: 2019

Journal Articles

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ghayathri Jeyakumar, MD, Hagop M. Kantarjian, MD, Kendra L. Sweet, MD, Cecilia Y Arana Yi, MD, Nitin Jain, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Brenda Walker, RN, Sherry R. Pierce, RN, BS, Tapan M. Kadia, MD, Farhad Ravandi, MD, Javier Pinilla, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4044.

https://doi.org/10.1182/blood.V122.21.4044.4044

Published: 2013

Journal Articles

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Cecilia Y Arana Yi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD, Ph.D., Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3557.

https://doi.org/10.1182/blood.V120.21.3557.3557

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Cecilia Y. Arana Yi, MD, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Laurie Ann Ford, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, George Deeb, MD, Paul K. Wallace, MS, PhD, Petr Starostik, MD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 4129.

https://doi.org/10.1182/blood.V114.22.4129.4129

Published: 2009

NARROW

Comparative Analysis for Effectiveness of Azacitidine Versus Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes with Marrow Fibrosis: A Single Institution Experience

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Email alerts

ASH Publications

American Society of Hematology

Comparative Analysis for Effectiveness of Azacitidine Versus Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes with Marrow Fibrosis: A Single Institution Experience

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only